Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab or Nimotuzumab in Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA
NCT05772208Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Jan 2022
- Primary completion
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab, nimotuzumab in nasopharyngeal carcinoma (NPC), sponsored by Fudan University. Started Jan 2022; status: recruiting.
02
Drugs
camrelizumabnimotuzumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05772208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05772208.